The American Medical Association is calling on the FDA to require botanical drug products, including kratom and cannabis, to prove safety and efficacy in clinical trials before they are marketed or prescribed, warning that unproven products can pose serious risks to patients. The AMA made its case in an Oct. 28 letter to FDA Deputy Commissioner Grace Graham. The physician group argued that rising consumer demand, anecdotal claims and influencer marketing on social media should not replace high-quality clinical trials or postmarket safety monitoring. AMA President Willie Underwood III, MD,… Originally published in Becker’s Hospital Review. Read More
AMA urges FDA to require clinical trials for botanical drug products
Integrated Psychiatric Consultants
Office Hours:Mon-Fri, 9 a.m. - 5 p.m. CT